Circulation

Vol. 153, Issue 8 Issue 8 2026
15
Articles

Articles in this Issue

Letter by Xie et al Regarding Article, “High-Volume Physical Activity and Clinical Coronary Artery Disease Outcomes: Findings From the Cooper Center Longitudinal Study”

Juan Xie, Li-ming Cheng, Kai Liu Feb 24, 2026 10.1161/circulationaha.125.075503

Retraction of: Proteasome-Dependent Degradation of Guanosine 5’-Triphosphate Cyclohydrolase I Causes Tetrahydrobiopterin Deficiency in Diabetes Mellitus

Jian Xu, Yong Wu, Ping Song et al. Feb 24, 2026 10.1161/cir.0000000000001420

Correction to: Pragmatic Approaches to the Evaluation and Monitoring of Artificial Intelligence in Health Care: A Science Advisory From the American Heart Association

Sneha S. Jain, Shinichi Goto, Jennifer L. Hall et al. Feb 24, 2026 10.1161/cir.0000000000001418

Inhibiting Fatty Acid Oxidation With a Mitotrope in Heart Failure With Preserved Ejection Fraction

Craig R. Malloy, Daniel Cheeran Feb 24, 2026 pp. 564-566 10.1161/circulationaha.125.078151

Response by Berry et al to Letter Regarding Article, “High-Volume Physical Activity and Clinical Coronary Artery Disease Outcomes: Findings From the Cooper Center Longitudinal Study”

Jarett D. Berry, David Leonard, Benjamin D. Levine et al. Feb 24, 2026 10.1161/circulationaha.125.077402

2025 ACC/AHA/HRS/ISACHD/SCAI Guideline for the Management of Adults With Congenital Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines

Michelle Gurvitz, Eric V. Krieger, Stephanie Fuller et al. Feb 24, 2026 10.1161/cir.0000000000001402

AIM The “2025 ACC/AHA/HRS/ISACHD/SCAI Guideline for the Management of Adults With Congenital Heart Disease” provides recommendations to guide clinicians on the evaluation and treat...

IMPROVE-DiCE, a 2-Part, Open-Label, Phase 2a Trial Evaluating the Safety and Effectiveness of Ninerafaxstat in Patients With Cardiometabolic Syndromes

Moritz J. Hundertmark, Sarah M. Birkhoelzer, Clara Portwood et al. Feb 24, 2026 pp. 550-563 10.1161/circulationaha.125.074041

BACKGROUND: We report IMPROVE-DiCE (Improve Diabetic Cardiac Energetics), a 2-part open-label, phase 2a trial evaluating the safety and effectiveness of ninerafaxstat, a novel ther...

Letter by Huang and Fogacci Regarding Article, “High-Volume Physical Activity and Clinical Coronary Artery Disease Outcomes: Findings From the Cooper Center Longitudinal Study”

Jian Huang, Federica Fogacci Feb 24, 2026 10.1161/circulationaha.125.075723

Socioeconomic and Structural Barriers to Addressing Obesity in Communities: A Scientific Statement From the American Heart Association

Stephanie T. Chung, Josephine Harrington, Namratha R. Kandula et al. Feb 24, 2026 10.1161/cir.0000000000001395

The obesity epidemic continues largely unabated, affecting more than one-third of the US population and disproportionately burdening individuals from socioeconomically disadvantaged populations. Numer...

Polygenic and Monogenic Contributions to Tachycardia-Associated Cardiomyopathy

Sina Safabakhsh, Paloma Jordà, Steffany Grondin et al. Feb 24, 2026 pp. 607-609 10.1161/circulationaha.125.076235

Increasingly Data-Driven ACHD Guidelines! Yet Considerable Room for Individualized Care

Keri M. Shafer, Sara A. Thorne, Rachael Cordina Feb 24, 2026 pp. 547-549 10.1161/circulationaha.125.077589

Environmental Stressors and Cardiovascular Health: Acting Locally for Global Impact in a Changing World: A Statement of the European Society of Cardiology, the American College of Cardiology, the American Heart Association, and the World Heart Federation

Thomas Münzel, Thomas Lüscher, Christopher M. Kramer et al. Feb 24, 2026 pp. 597-604 10.1161/circulationaha.125.079034

Non-communicable diseases (NCDs) account for 70% of global mortality and are responsible for over 38 million deaths annually, with cardiovascular disease (CVD) constituting most of these fatalities. W...

Systemic Embolic Events in Atrial Fibrillation: An Individual Patient Data Meta-analysis of 71 683 Participants Randomized to NOAC Versus Warfarin

Samer Al Said, Eugene Braunwald, Michael G. Palazzolo et al. Feb 24, 2026 pp. 567-575 10.1161/circulationaha.125.075275

BACKGROUND: Systemic embolic events (SEEs) are a serious but underrecognized complication of atrial fibrillation. Although non–vitamin K antagonist oral anticoagulants prevent isch...

Macrophage-Specific E3 Ubiquitin Ligase TRIM31 Reduces Atherosclerotic Plaque Formation by Targeting LOX-1

Jie Zhang, Liwen Yu, Wei Yang et al. Feb 24, 2026 pp. 576-596 10.1161/circulationaha.125.076514

BACKGROUND: Atherosclerosis is a chronic inflammatory disease marked by lipid accumulation and immune cell infiltration in arterial walls. Macrophages contribute by internalizing o...

Low-Dose Colchicine Attenuates Clonal Hematopoiesis in COLCOT

Jean-Claude Tardif, Lambert Busque, Steve Geoffroy et al. Feb 24, 2026 pp. 610-612 10.1161/circulationaha.125.077665

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0009-7322
E-ISSN 1524-4539
Subject Health Sciences
Language English
View Full Journal Page